Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. Andrew Brenner, development leader of an innovative drug portfolio platform that the company has recently licensed, is scheduled to conduct a live patient-focused webinar entitled, “A Promising New Radiotherapy for Recurrent Glioblastoma: An Introduction”, on Sunday, May 17, 2020, at 7 pm EDT.
May 12, 2020
· 6 min read